• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Alcon to block Mylan's bid for generic glaucoma med



Ft. Worth, TX-Alcon Research Ltd. has filed suit against Mylan Inc. to stop the pharmaceutical company from launching a generic form of Alcon’s Travatan Z.

The complaint states Mylan has sought FDA approval for its new drug application for eye drops containing the active ingredient travoprost-a product almost identical to Travatan Z-before the patents had expired.

Alcon says it was notified by Mylan in June that the generic-drug manufacturer had filed an application for FDA approval of an ophthalmic solution that contained “the same or equivalent ingredients in the same or equivalent amounts” as Travatan Z.

The patents covering the drug are less than 1 year old. Two patents were issued in September and December 2012, and the third was just approved in March, according to the suit.

Related Videos
Jacobi Cleaver, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.